U.S. markets closed

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
42.97+1.36 (+3.27%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close41.61
Open42.96
Bid42.95 x 1200
Ask43.09 x 800
Day's Range41.82 - 44.22
52 Week Range25.31 - 141.01
Volume512,893
Avg. Volume1,185,993
Market Cap5.576B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Misses Revenue Estimates

    Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -473.91% and -98.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

  • Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study
    Benzinga

    Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study

    Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in combination with BRII-179 (VBI-2601) for the treatment of chronic HBV infection. The open-label study is designed to evaluate the safety and efficacy of BRII-835 (VIR-2218) compared to the combination of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with and without interferon-alpha as a co-adjuvant. Brii Bio has led the design and implementation of this functional cure proof-of-concept study and is the sponsor of the Phase 2 study. BRII-835 (VIR-2218) is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. VBI-2601 (BRII-179) is a recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI's prophylactic 3-antigen HBV vaccine candidate and is designed to target enhanced B-cell and T-cell immunity. Price Action: VBIV shares 1.9% at $2.66, while VIR shares are down 1.9% at $47.5 in premarket trading on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaTrevena's TRV027 Included In Global COVID-19 StudyHouse Democrats Investigating Emergent BioSolutions' Vaccine Contracts, Call On Execs To Testify© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.